stockrowIDEAYA Biosciences, Inc.
IDYA Healthcare Biotechnology
IDEAYA Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $218.7 million, up 3,024.4% from fiscal 2024.
- Revenue
- −95.1%
- EPS
- −190.5%
- Free cash flow
- −165.9%
Quarter to September 2026, against a year earlier
Follow IDYA
Alert me
IDEAYA Biosciences, Inc. (IDYA) P/B ratio
As of 5 November 2026, IDEAYA Biosciences, Inc. (IDYA) trades at a P/B ratio of 2.9×. Over the past ten years it has ranged from 0.0× (June 2019) to 4.4× (February 2024); the current reading is higher than 73% of that period. That is above the Biotechnology industry median of 2.0× and above the Healthcare sector median of 2.3×.
P/B ratio, daily
Embed this chart
Annual newest first
| Period | P/B ratio | Change |
|---|---|---|
| FY2025 | 3.0× | 50.88% |
| FY2024 | 2.0× | (39.24%) |
| FY2023 | 3.3× | 58.25% |
| FY2022 | 2.1× | (25.42%) |
| FY2021 | 2.8× | 58.34% |
| FY2020 | 1.7× | — |
Quarterly newest first
| Period | P/B ratio | Change |
|---|---|---|
| Sep 2026 | 3.6× | 26.55% |
| Jun 2026 | 2.9× | (9.24%) |
| Mar 2026 | 3.2× | 5.45% |
| Dec 2025 | 3.0× | 35.57% |
| 15 more quarters | Free account |
Against its own ten years
P/B ratio against peers
| Company | P/B ratio |
|---|---|
| TLX Telix Pharmaceuticals Limited compare | n/m |
| CELC Celcuity, Inc. compare | n/m |
| BEAM Beam Therapeutics Inc. compare | 2.9× |
| IDYA IDEAYA Biosciences, Inc. | 2.9× |
| ELVN Enliven Therapeutics, Inc. compare | 3.3× |
| DNLI Denali Therapeutics Inc. compare | 4.0× |
| DYN Dyne Therapeutics, Inc. compare | 4.1× |
| VRDN Viridian Therapeutics, Inc. compare | 5.5× |
| TARS Tarsus Pharmaceuticals, Inc. compare | 30.1× |
| Biotechnology industry median | 2.0× |
| Healthcare sector median | 2.3× |
| Market median | 1.7× |
What P/B ratio is
Price to Book Value tells an investor how much the market pays for a company’s shares relative to the accounting net worth that belongs to common shareholders.
Stock Price ÷ (Common Equity (Total) (latest quarter) ÷ Shares (Basic, Weighted) (latest quarter))
More on IDYA
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement